Clinical Trial Update: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial compares sacituzumab govitecan-hziy plus pembrolizumab against physician's choice plus pembrolizumab in previously untreated locally advanced in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Triple Negative Breast Cancer, PD-L1 Positive | Phase 3 | Status: ACTIVE_NOT_RECRUITING